Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs Viral Infection Results in Approximately 20 Minutes

Why It Matters

Rapid, accurate infection differentiation enables clinicians to curb unnecessary antibiotic use, improving patient outcomes and delivering sizable cost savings for health systems.

Key Takeaways

• CE Mark granted for Access MeMed BV assay, 20‑minute results
• Test runs on Beckman’s DxI 9000 and Access 2 platforms
• Expected to cut up to £70 M ($89 M) avoidable European healthcare costs
• Real‑world data shows 82‑87% clinician decision impact
• Economic model predicts $170 K savings per 1,000 adult CAP cases

Pulse Analysis

The launch of Beckman Coulter’s Access MeMed BV assay marks a pivotal shift in laboratory diagnostics, marrying rapid turnaround with the scalability of existing immunoassay analyzers. By integrating MeMed’s host‑response technology into the DxI 9000 and Access 2 platforms, the test delivers bacterial versus viral differentiation in roughly 20 minutes—far quicker than traditional culture or PCR methods. This speed is critical in acute care settings where early therapeutic decisions can dramatically affect patient trajectories.

Beyond speed, the assay’s clinical performance is compelling. Real‑world evidence across nearly 6,000 patients indicates that physicians rely on the result to guide or change treatment plans in 82‑87% of cases, while validation studies report a negative predictive value approaching 99% for excluding bacterial infection. Such reliability supports antimicrobial stewardship initiatives, helping clinicians avoid unnecessary antibiotics that fuel resistance and expose patients to side‑effects. The rapid insight also reduces diagnostic uncertainty, a common driver of hospital admissions and extended stays.

From an economic perspective, the assay offers tangible savings. Health‑economic models estimate up to £70 million ($89 million) in avoidable costs across Europe, primarily through reduced admissions, fewer repeat tests, and more targeted antibiotic use. For every 1,000 suspected community‑acquired pneumonia cases, the model predicts roughly $170 K in adult cost savings and $134 K for pediatric cohorts. By leveraging existing laboratory infrastructure, the solution scales efficiently, positioning it as a cost‑effective tool for health systems seeking to improve outcomes while containing expenditures.